Overview

Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma

Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.
Phase:
Phase 2
Details
Lead Sponsor:
Accelerated Community Oncology Research Network
Collaborator:
Millennium Pharmaceuticals, Inc.
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Liposomal doxorubicin